Enfusion Stock Performance
| ENFN Stock | USD 11.09 0.02 0.18% |
Enfusion has a performance score of 4 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.23, which means not very significant fluctuations relative to the market. As returns on the market increase, Enfusion's returns are expected to increase less than the market. However, during the bear market, the loss of holding Enfusion is expected to be smaller as well. Enfusion right now shows a risk of 1.9%. Please confirm Enfusion information ratio, downside variance, day median price, as well as the relationship between the treynor ratio and kurtosis , to decide if Enfusion will be following its price patterns.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Enfusion are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of very unfluctuating technical and fundamental indicators, Enfusion may actually be approaching a critical reversion point that can send shares even higher in April 2025. ...more
Actual Historical Performance (%)
One Day Return 0.0903 | Five Day Return (0.81) | Year To Date Return 12.49 | Ten Year Return (44.07) | All Time Return (44.07) |
1 | Enfusion stock hits 52-week high at 10.75 amid growth - Investing.com | 12/17/2024 |
2 | Disposition of 24443 shares by Bradley Herring of Enfusion at 10.61 subject to Rule 16b-3 | 12/20/2024 |
3 | Enfusion Inc Under Investigation for Proposed Sale to Clearwater Analytics | 01/13/2025 |
4 | Disposition of 150000 shares by Oleg Movchan of Enfusion at 10.09 subject to Rule 16b-3 | 01/24/2025 |
5 | Analysts Set Enfusion, Inc. Target Price at 10.50 | 02/13/2025 |
6 | ENFN Stock Alert Halper Sadeh LLC Is Investigating Whether the Sale of Enfusion, Inc. Is Fair to Shareholders - The Bakersfield Californian | 02/24/2025 |
7 | ENFN Stock Alert Halper Sadeh LLC Is Investigating Whether the Sale of Enfusion, Inc. Is Fair to Shareholders | 02/25/2025 |
8 | Acquisition by Bradley Herring of 58202 shares of Enfusion subject to Rule 16b-3 | 02/26/2025 |
9 | Clearwater Analytics and Enfusion Announce Expiration of Hart-Scott-Rodino Act Waiting Period For Proposed Acquisition of Enfusion | 02/27/2025 |
10 | Disposition of 540 shares by Valeria Gutowski of Enfusion at 11.42 subject to Rule 16b-3 | 02/28/2025 |
11 | Enfusion Inc Reports Strong Q4 and Full Year 2024 Financial Results | 03/03/2025 |
12 | Disposition of 1233 shares by Valeria Gutowski of Enfusion at 11.365 subject to Rule 16b-3 | 03/04/2025 |
13 | Disposition of 4645 shares by Bradley Herring of Enfusion at 11.375 subject to Rule 16b-3 | 03/05/2025 |
14 | Disposition of 11452 shares by Oleg Movchan of Enfusion at 11.393 subject to Rule 16b-3 | 03/06/2025 |
15 | Bradley Herring Sells 1,533 Shares of Enfusion, Inc. Stock | 03/07/2025 |
| Begin Period Cash Flow | 35.6 M |
Enfusion |
Enfusion Relative Risk vs. Return Landscape
If you would invest 1,047 in Enfusion on December 19, 2024 and sell it today you would earn a total of 62.00 from holding Enfusion or generate 5.92% return on investment over 90 days. Enfusion is currently generating 0.115% in daily expected returns and assumes 1.8955% risk (volatility on return distribution) over the 90 days horizon. In different words, 16% of stocks are less volatile than Enfusion, and 98% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Enfusion Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Enfusion's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Enfusion, and traders can use it to determine the average amount a Enfusion's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0607
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | ENFN | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 1.9 actual daily | 16 84% of assets are more volatile |
Expected Return
| 0.12 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.06 actual daily | 4 96% of assets perform better |
Based on monthly moving average Enfusion is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Enfusion by adding it to a well-diversified portfolio.
Enfusion Fundamentals Growth
Enfusion Stock prices reflect investors' perceptions of the future prospects and financial health of Enfusion, and Enfusion fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Enfusion Stock performance.
| Return On Equity | 0.0442 | ||||
| Return On Asset | 0.0305 | ||||
| Profit Margin | 0.01 % | ||||
| Operating Margin | 0.03 % | ||||
| Current Valuation | 1.02 B | ||||
| Shares Outstanding | 94.8 M | ||||
| Price To Earning | 0.11 X | ||||
| Price To Book | 14.36 X | ||||
| Price To Sales | 5.21 X | ||||
| Revenue | 201.61 M | ||||
| Gross Profit | 136.74 M | ||||
| EBITDA | 6.16 M | ||||
| Net Income | 3.92 M | ||||
| Cash And Equivalents | 56.56 M | ||||
| Cash Per Share | 0.84 X | ||||
| Total Debt | 20.31 M | ||||
| Current Ratio | 9.17 X | ||||
| Book Value Per Share | 0.77 X | ||||
| Cash Flow From Operations | 34.68 M | ||||
| Earnings Per Share | 0.03 X | ||||
| Market Capitalization | 1.05 B | ||||
| Total Asset | 143.26 M | ||||
| Retained Earnings | (170.11 M) | ||||
| Working Capital | 66.19 M | ||||
About Enfusion Performance
By examining Enfusion's fundamental ratios, stakeholders can obtain critical insights into Enfusion's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Enfusion is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 42.58 | 44.71 | |
| Return On Tangible Assets | 0.02 | 0.02 | |
| Return On Capital Employed | 0.05 | 0.06 | |
| Return On Assets | 0.02 | 0.02 | |
| Return On Equity | 0.04 | 0.04 |
Things to note about Enfusion performance evaluation
Checking the ongoing alerts about Enfusion for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Enfusion help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Enfusion is unlikely to experience financial distress in the next 2 years | |
| Enfusion has a very strong financial position based on the latest SEC filings | |
| Over 97.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from thelincolnianonline.com: Bradley Herring Sells 1,533 Shares of Enfusion, Inc. Stock |
- Analyzing Enfusion's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Enfusion's stock is overvalued or undervalued compared to its peers.
- Examining Enfusion's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Enfusion's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Enfusion's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Enfusion's stock. These opinions can provide insight into Enfusion's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enfusion. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. To learn how to invest in Enfusion Stock, please use our How to Invest in Enfusion guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Application Software space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enfusion. If investors know Enfusion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enfusion listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.82) | Earnings Share 0.03 | Revenue Per Share | Quarterly Revenue Growth 0.139 | Return On Assets |
The market value of Enfusion is measured differently than its book value, which is the value of Enfusion that is recorded on the company's balance sheet. Investors also form their own opinion of Enfusion's value that differs from its market value or its book value, called intrinsic value, which is Enfusion's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enfusion's market value can be influenced by many factors that don't directly affect Enfusion's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enfusion's value and its price as these two are different measures arrived at by different means. Investors typically determine if Enfusion is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enfusion's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.